Combination of tamoxifen, aminoglutethimide, danazol and medroxyprogesterone acetate in advanced breast cancer

Janet Hardy, Trevor J. Powles, Ian Judson, H D Sinnett, S. Ashley, R. Charles Coombes, Caroline L. Ellin
In: European Journal of Cancer and Clinical Oncology · 1990 · vol. 26(7) , pp. 824–827 · doi:10.1016/0277-5379(90)90162-m · PMID:2145904 · W2069570057
article OA: closed CC0
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-13 ⓘ

This paper investigated the combination of tamoxifen, aminoglutethimide, danazol, and medroxyprogesterone acetate in patients with advanced breast cancer.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Seventy-four post-menopausal women with metastatic breast cancer were treated with a combination hormonal regimen consisting of tamoxifen, aminoglutethimide danazol and medroxyprogesterone acetate (POND). 72% of the patients had received no previous treatment. The overall response rate (complete and partial remission) was 43.5% with a median response duration of 19 months and a median survival of 27 months. The most common sites of response were in regional nodes and local chest wall disease. The major side-effects were those expected from the individual agents: nausea, lethargy, rash and oedema.

My notes (saved in your browser only)

Citation neighborhood (sparse)

Too few in-corpus citations on either side for a chart; here are the lists.

Cites (4)

References (25)

SciLite annotations

chemicals 10
tamoxifen aminoglutethimide danazol medroxyprogesterone acetate tamoxifen aminoglutethimide danazol medroxyprogesterone acetate

Source provenance

openalex
last seen: 2026-05-11T05:49:40.447239+00:00
scilite
last seen: 2026-05-18T04:57:49.680383+00:00
License: CC0 · commercial use OK